Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease

Neuropsychopharmacology

Volumn 41, Issue 8, 2016, Pages 2171-2177

  Borchert, Robin J ^a   Rittman, Timothy ^a   Passamonti, Luca ^a,b   Ye, Zheng ^c   Sami, Saber ^a   Jones, Simon P ^a   Nombela, Cristina ^d   Vázquez Rodríguez, Patricia ^a   Vatansever, Deniz ^a   Rae, Charlotte L ^e,f   Hughes, Laura E ^a,g   Robbins, Trevor W ^h   Rowe, James B ^a,g,h  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CNR   (Italy)

^c INSTITUTE OF PSYCHOLOGY   (China)

^d TECHNICAL UNIVERSITY OF CARTAGENA   (Spain)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

^f BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^g MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT;

AGED; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CONNECTOME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DORSAL ANTERIOR CINGULATE CORTEX; DORSOLATERAL PREFRONTAL CORTEX; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; INFERIOR FRONTAL GYRUS; MALE; MAXIMUM PLASMA CONCENTRATION; MINI MENTAL STATE EXAMINATION; NERVE CELL NETWORK; NEUROMODULATION; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNIFIED PARKINSON DISEASE RATING SCALE; BRAIN MAPPING; DRUG EFFECTS; MIDDLE AGED; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY;

ADRENERGIC UPTAKE INHIBITORS; AGED; ATOMOXETINE HYDROCHLORIDE; BRAIN MAPPING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEURAL PATHWAYS; PARKINSON DISEASE; PREFRONTAL CORTEX;

EID: 84959463783     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.18     Document Type: Article

References (50)

1. Arnsten AFT (2011). Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 69: e89-e99.
2. Ashburner J (2007). A fast diffeomorphic image registration algorithm. NeuroImage 38(95): 113.
3. Bari A, Eagle DM, Mar AC, Robinson ESJ, Robbins TW (2009). Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. Psychopharmacology (Berl) 205: 273-283.
4. Biesbroek JM, Zandvoort MJE van, Kappelle LJ, Velthuis BK, Biessels GJ, Postma A (2015). Shared and distinct anatomical correlates of semantic and phonemic fluency revealed by lesion-symptom mapping in patients with ischemic stroke. Brain Struct Funct (e-pub ahead of print; doi:10.1007/s00429-015-1033-8).
5. Botvinick MM, Cohen JD, Carter CS (2004). Conflict monitoring and anterior cingulate cortex: an update. Trends Cogn Sci (Regul Ed) 8: 539-546.
6. Braak H, Rüb U, Gai WP, Tredici KD (2003). Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517-536.
7. Braver TS, Barch DM, Gray JR, Molfese DL, Snyder A (2001). Anterior cingulate cortex and response conflict: effects of frequency, inhibition and errors. Cereb Cortex 11: 825-836.
8. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
9. Carli M, Robbins TW, Evenden JL, Everitt BJ (1983). Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 9: 361-380.
10. Chamberlain SR, Hampshire A, Müller U, Rubia K, Del Campo N, Craig K et al (2009). Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65: 550-555.
11. Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer M, Simmons A et al (2014). Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory. Psychol Med 44: 633-646.
12. Cuenod CA, Bookheimer SY, Hertz-Pannier L, Zeffiro TA, Theodore WH, Le Bihan D (1995). Functional MRI during word generation, using conventional equipment: a potential tool for language localization in the clinical environment. Neurology 45: 1821-1827.
13. Florin-Lechner SM, Druhan JP, Aston-Jones G, Valentino RJ (1996). Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res 742: 89-97.
14. Frith CD, Friston K, Liddle PF, Frackowiak RS (1991). Willed action and the prefrontal cortex in man: a study with PET. Proc Biol Sci 244: 241-246.
15. Gaillard WD, Hertz-Pannier L, Mott SH, Barnett AS, LeBihan D, Theodore WH (2000). Functional anatomy of cognitive development: fMRI of verbal fluency in children and adults. Neurology 54: 180-185.
16. Gauthier CT, Duyme M, Zanca M, Capron C (2009). Sex and performance level effects on brain activation during a verbal fluency task: a functional magnetic resonance imaging study. Cortex 45: 164-176.
17. Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC (2011). Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 18: 703-710.
18. Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J et al (2014). Targeting impulsivity in Parkinson's disease using atomoxetine. Brain 137: 1986-1997.
19. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (2010). Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 114: 259-270.
20. Kwak Y, Peltier S, Bohnen NI, Müller ML, Dayalu P, Seidler RD (2010). Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson's disease. Front Syst Neurosci 4: 143.
21. Kwak Y, Peltier SJ, Bohnen NI, Müller ML, Dayalu P, Seidler RD (2012). L-DOPA changes spontaneous low-frequency BOLD signal oscillations in Parkinson's disease: a resting state fMRI study. Front Syst Neurosci 6: 52.
22. Lapiz MDS, Morilak DA (2006). Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137: 1039-1049.
23. Levy BJ, Wagner AD (2011). Cognitive control and right ventrolateral prefrontal cortex: reflexive reorienting, motor inhibition, and action updating. Ann NY Acad Sci 1224: 40-62.
24. Marsh L, Biglan K, Gerstenhaber M, Williams JR (2009). Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 24: 277-282.
25. Moeller SJ, Honorio J, Tomasi D, Parvaz MA, Woicik PA, Volkow ND et al (2014). Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction. Cereb Cortex 24: 643-653.
26. Newman LA, Darling J, McGaughy J (2008). Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl) 200: 39-50.
27. Olde Dubbelink KTE, Schoonheim MM, Deijen JB, Twisk JWR, Barkhof F, Berendse HW (2014). Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology 83: 2046-2053.
28. Patel AX, Kundu P, Rubinov M, Jones PS, Vértes PE, Ersche KD et al (2014). A wavelet method for modeling and despiking motion artifacts from resting-state fMRI time series. NeuroImage 95: 287-304.
29. Pereira JB, Junqué C, Bartrés-Faz D, Martí MJ, Sala-Llonch R, Compta Y et al (2013). Modulation of verbal fluency networks by transcranial direct current stimulation (tDCS) in Parkinson's disease. Brain Stimul 6: 16-24.
30. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE (2012). Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. NeuroImage 59: 2142-2154.
31. Price CJ, Friston KJ (1999). Scanning patients with tasks they can perform. Hum Brain Mapp 8: 102-108.
32. Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB (2012). White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. NeuroImage 62: 1675-1684.
33. Rae CL, Hughes LE, Anderson MC, Rowe JB (2015). The prefrontal cortex achieves inhibitory control by facilitating subcortical motor pathway connectivity. J Neurosci 35: 786-794.
34. Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH et al (2013). The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84: 544-551.
35. Robbins TW, Arnsten AFT (2009). The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32: 267-287.
36. Robinson ESJ, Eagle DM, Mar AC, Bari A, Banerjee G, Jiang X et al (2008). Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 33: 1028-1037.
37. Rowe JB, Hughes LE, Barker RA, Owen AM (2010). Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment? NeuroImage 52: 1015-1026.
38. Rowe JB, Hughes L, Ghosh BCP, Eckstein D, Williams-Gray CH, Fallon S et al (2008). Parkinson's disease and dopaminergic therapy - differential effects on movement, reward and cognition. Brain 131: 2094-2105.
39. Sauer J-M, Ring BJ, Witcher JW (2005). Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44: 571-590.
40. Sharp DJ, Bonnelle V, Boissezon XD, Beckmann CF, James SG, Patel MC et al (2010). Distinct frontal systems for response inhibition, attentional capture, and error processing. Proc Natl Acad Sci USA 107: 6106-6111.
41. Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE et al (2009). Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci USA 106: 13040-13045.
42. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010). Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25: 2649-2653.
43. Vazey EM, Aston-Jones G (2012). The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front Behav Neurosci 6: 48.
44. Watson GS, Leverenz JB (2010). Profile of cognitive impairment in Parkinson's disease. Brain Pathol 20: 640-645.
45. Weintraub D, Siderowf AD, Potenza MN et al (2006). Association of dopamine agonist use with impulse control disorders in parkinson disease. Arch Neurol 63: 969-973.
46. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA (2007). Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130: 1787-1798.
47. Yao N, Shek-Kwan Chang R, Cheung C, Pang S, Lau KK, Suckling J et al (2014). The default mode network is disrupted in parkinson's disease with visual hallucinations. Hum Brain Mapp 35: 5658-5666.
48. Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ et al (2013). Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 82: 308-316.
49. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T et al (2015). Improving response inhibition in Parkinson's disease with atomoxetine. Biol Psychiatry 77: 740-748.
50. Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS et al (2016). Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Hum Brain Mapp 37: 1026-1037.